After the US Securities & Exchange Commission, the Food & Drug Administration: the equity and bond market regulator has not made any formal comment but as we reported, firms on Wall Street such as Smith Barney no longer trust Pentium machines not to dump them in deep trouble with the regulator, but the folks at Food & Drug are taking a more proactive role, saying that since getting new drugs approved for commercial use, pharmaceutical manufacturers are required to supply the Administration with exhaustive data from clinical trials, and that if any of the vast sums involved were done on a Pentium machine there is potential for error; the Pharmaceutical Research & Manufacturers Association has been informally requested to notify members that the Administration has some concerns about data from Pentiums.
